<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092089</url>
  </required_header>
  <id_info>
    <org_study_id>ST2017-Pro00067953</org_study_id>
    <secondary_id>Pro00067953</secondary_id>
    <nct_id>NCT03092089</nct_id>
  </id_info>
  <brief_title>Sonothrombolysis in Patients With STEMI</brief_title>
  <official_title>Sonothrombolysis in Patients With an ST-segment Elevation Myocardial Infarction. A Prospective Single-arm Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harald Becher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates what effect sonothrombolysis may have on spontaneous reperfusion,&#xD;
      microvascular obstruction, left ventricular function and infarct size in patients presenting&#xD;
      with their first ST-segment Elevation Myocardial Infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, single-arm study that examines pre-procedural&#xD;
      sonothrombolysis as an adjuvant to contemporary therapy in patients with ST-segment elevation&#xD;
      myocardial infarction receiving PPCI.This study is to examine what effect adding emergent&#xD;
      diagnostic ultrasound (DUS) guided high mechanical index (HMI) impulses (sonothrombolysis),&#xD;
      applied both before and after primary percutaneous coronary intervention (PPCI) during an&#xD;
      intravenous commercially available microbubble infusion (Definity), have on spontaneous&#xD;
      reperfusion (i.e. pre PCI coronary artery patency rates), microvascular obstruction, left&#xD;
      ventricular function and infarct size in patients presenting with their first ST-segment&#xD;
      Elevation Myocardial Infarction.&#xD;
&#xD;
      Patients will immediately receive an intravenous infusion of commercially available&#xD;
      ultrasound contrast agent (Definity). After starting the infusion, myocardial contrast&#xD;
      echocardiography will be performed. 4-, 2- and 3-chamber views will be recorded to document&#xD;
      the size of the perfusion defect. Loops of 15 cardiac cycles will be recorded using low&#xD;
      mechanical index (MI) ultrasound with a 'flash' delivered after the second cardiac cycle of&#xD;
      the loop. The flash is a short impulse of HMI ultrasound which is transmitted to destroy the&#xD;
      ultrasound contrast in the myocardium and then to assess the replenishment of myocardial&#xD;
      contrast. These recordings will also be used to assess regional wall motion as well as the LV&#xD;
      volumes and ejection fraction. Immediately after the diagnostic ultrasound, the therapeutic&#xD;
      ultrasound will start using the same transducer by applying multiple HMI ultrasound impulses.&#xD;
      The HMI are the same as those which are used for assessment of myocardial perfusion in&#xD;
      diagnostic ultrasound. These pulses will be applied in the apical 4-, 2-, and 3-chamber views&#xD;
      to the apical windows that contained the risk area. The intervals between HMI impulses will&#xD;
      vary from 5 to 15 s depending on the time required for myocardial contrast replenishment.&#xD;
      Diagnostic echocardiography will also be scheduled prior to discharge (Day2) and 90 days post&#xD;
      procedure.&#xD;
&#xD;
      If this study is successful, a larger study will be designed in order to collect the evidence&#xD;
      for using contrast ultrasound for treatment of myocardial infarction in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">October 3, 2019</completion_date>
  <primary_completion_date type="Actual">October 3, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This clinical study is a prospective single-center, single-arm investigation of sonothrombolysis in adult patients presenting with high-risk STEMI within 6 hrs of the onset of clinical symptoms and receiving reperfusion therapy with PCI. All patients will receive standard therapy. Patients will immediately receive an iv infusion of commercially available ultrasound contrast agent (Definity) and myocardial contrast echocardiography will be performed to document the size of the perfusion defect. Loops of 15 cardiac cycles will be recorded using low mechanical index (MI) ultrasound. These recordings will also be used to assess regional wall motion as well as LV volumes and ejection fraction. Immediately after the diagnostic ultrasound, the therapeutic ultrasound will start using the same transducer by applying multiple high MI ultrasound impulses. These pulses will be applied to the apical windows that contained the risk area. The intervals between HMI impulses will vary from 5 to 15 s.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Spontaneous Reperfusion</measure>
    <time_frame>Day 1</time_frame>
    <description>Spontaneous reperfusion as assessed by a pre PCI ECG complete ST-segment resolution (&gt;50%) (immediately prior to angiogram)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Spontaneous Reperfusion</measure>
    <time_frame>Day 1</time_frame>
    <description>Spontaneous reperfusion as assessed by a pre PCI TIMI 2-3 flow on diagnostic angiogram (immediately prior to angiogram)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete (&gt;50%) ST-segment Resolution at 30 Minutes Post PCI</measure>
    <time_frame>Day 1</time_frame>
    <description>Complete ST-segment resolution as assessed by the worst lead on electrocardiogram (ECG core lab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF) by Echocardiography (ECHO) (Simpson Method)</measure>
    <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
    <description>assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and day 90±2 days after infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wall Motion Score Index (WMSI) by ECHO</measure>
    <time_frame>Day 1, Day 3±2 , 3 month Follow Up</time_frame>
    <description>Mean Regional Wall Motion Score Index assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and 90±2 days after infarction. The wall motion score is determined by visual assessment of the regional wall LV wall motion in the three apical echocardiographic views. The wall motion score of LV segments is dimensionless: normal 1, hypokinetic 2, akinetic 3, dyskinetic 4. The wall motion score index is the sum of all segmental scores divided by the number of segments analyzed (scale 1-4). A wall motion score index of 1 is normal. The worse the wall motion score index the worse is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular Perfusion Score Index (MPSI) by ECHO</measure>
    <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
    <description>Mean microvascular perfusion score index (MPSI) assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and 90±2 days after infarction The microvascular perfusion score is determined by visual assessment of the LV segments in the three apical echocardiographic views. The microvascular perfusion score of LV segments is dimensionless: normal 1, mildly reduced perfusion 2, no perfusion displayed 3. The microvascular perfusion score index score index is the sum of all segmental scores divided by the number of segments analyzed (scale 1 -3). A microvascular perfusion score index of 1 is normal. The worse the microvascular perfusion score index the worse is the outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Allergic Reaction to Definity®</measure>
    <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
    <description>Number of participants who recorded any allergic reaction to Definity</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Vasospasm in Culprit Coronary Artery</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants who recorded any vasospasm due to high impulse ultrasound</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
    <description>Number of participants who recorded any adverse events that as per protocol are not related to acute myocardial infarction</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Adult patients with high risk STEMI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Definity, (Lipid Microspheres) Intravenous Suspension</intervention_name>
    <description>Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI</description>
    <arm_group_label>Adult patients with high risk STEMI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Myocardial Contrast Echocardiography</intervention_name>
    <description>Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up</description>
    <arm_group_label>Adult patients with high risk STEMI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Repurfusion therapy with PPCI</intervention_name>
    <description>Patients will receive reperfusion therapy with PPCI as standard of care</description>
    <arm_group_label>Adult patients with high risk STEMI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients presenting with STEMI within 6 hours of symptom onset and:&#xD;
&#xD;
          1. Are expected to receive reperfusion therapy with primary PCI&#xD;
&#xD;
          2. Have a high-risk STEMI ECG defined as:&#xD;
&#xD;
               -  ≥2mm ST-segment elevation in 2 anterior or lateral leads; or&#xD;
&#xD;
               -  ≥2 mm ST-segment elevation in 2 inferior leads coupled with ST segment depression&#xD;
                  in 2 contiguous anterior leads for a total ST-segment deviation of ≥4mm&#xD;
&#xD;
          3. Age ≥30 years.&#xD;
&#xD;
          4. Adequate apical and/or parasternal images by echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated inferior STEMI without anterior ST-segment depression&#xD;
&#xD;
          2. Previous coronary bypass surgery&#xD;
&#xD;
          3. Cardiogenic shock&#xD;
&#xD;
          4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study&#xD;
&#xD;
          5. Life expectancy of less than two months or terminally ill.&#xD;
&#xD;
          6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors,&#xD;
             anticoagulants, or aspirin&#xD;
&#xD;
          7. Known large right to left intracardiac shunts.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Becher</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mazankowski Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Slikkerveer J, Kleijn SA, Appelman Y, Porter TR, Veen G, van Rossum AC, Kamp O. Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: pilot of the Sonolysis study. Ultrasound Med Biol. 2012 Feb;38(2):247-52. doi: 10.1016/j.ultrasmedbio.2011.11.001. Epub 2011 Dec 16.</citation>
    <PMID>22178160</PMID>
  </reference>
  <reference>
    <citation>Xie F, Lof J, Everbach C, He A, Bennett RM, Matsunaga T, Johanning J, Porter TR. Treatment of acute intravascular thrombi with diagnostic ultrasound and intravenous microbubbles. JACC Cardiovasc Imaging. 2009 Apr;2(4):511-8. doi: 10.1016/j.jcmg.2009.02.002.</citation>
    <PMID>19580735</PMID>
  </reference>
  <reference>
    <citation>Roos ST, Juffermans LJ, van Royen N, van Rossum AC, Xie F, Appelman Y, Porter TR, Kamp O. Unexpected High Incidence of Coronary Vasoconstriction in the Reduction of Microvascular Injury Using Sonolysis (ROMIUS) Trial. Ultrasound Med Biol. 2016 Aug;42(8):1919-28. doi: 10.1016/j.ultrasmedbio.2016.03.032. Epub 2016 May 6.</citation>
    <PMID>27160847</PMID>
  </reference>
  <reference>
    <citation>Mathias W Jr, Tsutsui JM, Tavares BG, Xie F, Aguiar MO, Garcia DR, Oliveira MT Jr, Soeiro A, Nicolau JC, Lemos PA Neto, Rochitte CE, Ramires JA, Kalil R Filho, Porter TR. Diagnostic Ultrasound Impulses Improve Microvascular Flow in Patients With STEMI Receiving Intravenous Microbubbles. J Am Coll Cardiol. 2016 May 31;67(21):2506-15. doi: 10.1016/j.jacc.2016.03.542.</citation>
    <PMID>27230046</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <results_first_submitted>April 16, 2021</results_first_submitted>
  <results_first_submitted_qc>May 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Harald Becher</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sonothrombolysis, STEMI, PPCI, Microbubbles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03092089/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03092089/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adult Patients With High Risk STEMI</title>
          <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adult Patients With High Risk STEMI</title>
          <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Spontaneous Reperfusion</title>
        <description>Spontaneous reperfusion as assessed by a pre PCI ECG complete ST-segment resolution (&gt;50%) (immediately prior to angiogram)</description>
        <time_frame>Day 1</time_frame>
        <population>for patients did not have a pre PCI ECG</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Spontaneous Reperfusion</title>
          <description>Spontaneous reperfusion as assessed by a pre PCI ECG complete ST-segment resolution (&gt;50%) (immediately prior to angiogram)</description>
          <population>for patients did not have a pre PCI ECG</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Spontaneous Reperfusion</title>
        <description>Spontaneous reperfusion as assessed by a pre PCI TIMI 2-3 flow on diagnostic angiogram (immediately prior to angiogram)</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Spontaneous Reperfusion</title>
          <description>Spontaneous reperfusion as assessed by a pre PCI TIMI 2-3 flow on diagnostic angiogram (immediately prior to angiogram)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete (&gt;50%) ST-segment Resolution at 30 Minutes Post PCI</title>
        <description>Complete ST-segment resolution as assessed by the worst lead on electrocardiogram (ECG core lab)</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete (&gt;50%) ST-segment Resolution at 30 Minutes Post PCI</title>
          <description>Complete ST-segment resolution as assessed by the worst lead on electrocardiogram (ECG core lab)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF) by Echocardiography (ECHO) (Simpson Method)</title>
        <description>assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and day 90±2 days after infarction</description>
        <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
        <population>EF</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF) by Echocardiography (ECHO) (Simpson Method)</title>
          <description>assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and day 90±2 days after infarction</description>
          <population>EF</population>
          <units>% ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EF at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF Day 3+/-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF Day 1 post PCI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF Day 1 pre PCI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF Day 1 admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wall Motion Score Index (WMSI) by ECHO</title>
        <description>Mean Regional Wall Motion Score Index assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and 90±2 days after infarction. The wall motion score is determined by visual assessment of the regional wall LV wall motion in the three apical echocardiographic views. The wall motion score of LV segments is dimensionless: normal 1, hypokinetic 2, akinetic 3, dyskinetic 4. The wall motion score index is the sum of all segmental scores divided by the number of segments analyzed (scale 1-4). A wall motion score index of 1 is normal. The worse the wall motion score index the worse is the outcome.</description>
        <time_frame>Day 1, Day 3±2 , 3 month Follow Up</time_frame>
        <population>Wall Motion Score Index (WMSI)</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Wall Motion Score Index (WMSI) by ECHO</title>
          <description>Mean Regional Wall Motion Score Index assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and 90±2 days after infarction. The wall motion score is determined by visual assessment of the regional wall LV wall motion in the three apical echocardiographic views. The wall motion score of LV segments is dimensionless: normal 1, hypokinetic 2, akinetic 3, dyskinetic 4. The wall motion score index is the sum of all segmental scores divided by the number of segments analyzed (scale 1-4). A wall motion score index of 1 is normal. The worse the wall motion score index the worse is the outcome.</description>
          <population>Wall Motion Score Index (WMSI)</population>
          <units>dimensionless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WMSI 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WMSI Day 3+/-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WMSI Day 1 post PCI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WMSI Day 1 pre PCI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WMSI Day 1 admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microvascular Perfusion Score Index (MPSI) by ECHO</title>
        <description>Mean microvascular perfusion score index (MPSI) assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and 90±2 days after infarction The microvascular perfusion score is determined by visual assessment of the LV segments in the three apical echocardiographic views. The microvascular perfusion score of LV segments is dimensionless: normal 1, mildly reduced perfusion 2, no perfusion displayed 3. The microvascular perfusion score index score index is the sum of all segmental scores divided by the number of segments analyzed (scale 1 -3). A microvascular perfusion score index of 1 is normal. The worse the microvascular perfusion score index the worse is the outcome.</description>
        <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
        <population>Microvascular Perfusion Score Index (MPSI)</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Microvascular Perfusion Score Index (MPSI) by ECHO</title>
          <description>Mean microvascular perfusion score index (MPSI) assessed on day 1 (pre and post reperfusion), day 3±2 (discharge) and 90±2 days after infarction The microvascular perfusion score is determined by visual assessment of the LV segments in the three apical echocardiographic views. The microvascular perfusion score of LV segments is dimensionless: normal 1, mildly reduced perfusion 2, no perfusion displayed 3. The microvascular perfusion score index score index is the sum of all segmental scores divided by the number of segments analyzed (scale 1 -3). A microvascular perfusion score index of 1 is normal. The worse the microvascular perfusion score index the worse is the outcome.</description>
          <population>Microvascular Perfusion Score Index (MPSI)</population>
          <units>dimensionless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPSI 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPSI Day 3+/-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPSI Day 1 post PCI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPSI Day 1 pre PCI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPSI Day 1 admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Allergic Reaction to Definity®</title>
        <description>Number of participants who recorded any allergic reaction to Definity</description>
        <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Allergic Reaction to Definity®</title>
          <description>Number of participants who recorded any allergic reaction to Definity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Vasospasm in Culprit Coronary Artery</title>
        <description>Number of participants who recorded any vasospasm due to high impulse ultrasound</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vasospasm in Culprit Coronary Artery</title>
          <description>Number of participants who recorded any vasospasm due to high impulse ultrasound</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants who recorded any adverse events that as per protocol are not related to acute myocardial infarction</description>
        <time_frame>Day 1, Day 3±2, 3 month Follow Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Patients With High Risk STEMI</title>
            <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants who recorded any adverse events that as per protocol are not related to acute myocardial infarction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adult Patients With High Risk STEMI</title>
          <description>Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)&#xD;
Definity, (Lipid Microspheres) Intravenous Suspension: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI&#xD;
Myocardial Contrast Echocardiography: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up&#xD;
Repurfusion therapy with PPCI: Patients will receive reperfusion therapy with PPCI as standard of care</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Fibrillation Arrest during angiography</sub_title>
                <description>Defibrillation with prompt recurrence of sinus rhythm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>LV thrombus displayed at discharge echocardiogram</sub_title>
                <description>Patient was admitted to initiate Warfarin treatment and intravenous heparin until therapeutic coagulation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Congestive heart failure due to severe mitral regurgitation</sub_title>
                <description>Medical treatment for congestive heart failure and mitral valve replacement</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>congestive heart failure</sub_title>
                <description>shortness of breath, congestive was treated with furosemide and the patient improved</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>post myocardial infarct pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>small loculated pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>exertional breathlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting after morphine injection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia after angiography</sub_title>
                <description>improved and patient referred to neurology</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Kevin Bainey</name_or_title>
      <organization>University of Alberta Hospital</organization>
      <phone>780-407-2176</phone>
      <email>Kevin.Bainey@albertahealthservices.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

